Comment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Cancer"
DOI: 10.1038/s41416-020-01103-0
Abstract: We agree in principle with our colleagues’ endorsement in this journal of the use of the tropomyosin receptor kinase (TRK) inhibitor LOXO-101 (larotrectinib) in children. Our enthusiasm for the accelerated deployment of LOXO-101 has been… read more here.
Keywords: comment tumour; tumour agnostic; trk; loxo 101 ... See more keywords